2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1429

Patient-Reported Outcomes Measures and Economical Burden of Patients with Ankylosing Spondylitis in a Chinese Prospective Cohort with Smart Management System for Spondyloarthritis

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1741

Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1327

Patients with Chikungunya Fever Have Increased Serum Levels of Proinflamatory Cytokines

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1503

Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1498

Patterns of Interstitial Lung Disease and Associated Mortality in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1842

Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1378

Pentraxin-3 Level Predicts Vasculitis and Mucocutaneous Involvement in Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1174

Perceived Stress and Reported Cognitive Symptoms Among Patients with Systemic Lupus Erythematosus

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1070

Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients

Antiphospholipid Syndrome - Poster I

9:00AM-11:00AM: Abstract Number: 1292

Performance of 18fluoride Sodium Positron Emission Tomography with Computed Tomography to Assess Inflammatory and Structural Sacroiliitis Respectively on Magnetic Resonance Imaging and Computed Tomography in Axial Spondyloarthritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1291

Performance of Magnetic Resonance Imaging and 18fluoride Sodium Positron Emission Tomography with Computed Tomography to Assess Inflammatory and Structural Abnormalities of the Sacroiliac Joint in Axial Spondyloarthritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1095

Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1602

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1285

PET/CT Imaging in Patients with Vascular Behcet Disease

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1642

Pharmacokinetic-Pharmacodynamic Analysis of GS-4059-Mediated Bruton’s Tyrosine Kinase Inhibition

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].